top of page
Diese Website wurde mit dem Homepage-Baukasten von
.com
erstellt. Erstelle deine Website noch heute.Gleich loslegen

Schwerpunkt auf Lebensqualität, Entzündung etc.

 

 

  •          Carr, A. C., M. C. Vissers, et al. (2014). "The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life." Front Oncol 4: 283.

The Effect of Intravenous Vitamin C on Cancer- and Chemotherapy-Related Fatigue and Quality of Life

 

  •          Ma, Y., J. Chapman, et al. (2014). "High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy." Sci Transl Med 6(222): 222ra218 (Ma, Chapman et al. 2014)

High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. - PubMed - NCBI

 

 

 

  •          Mikirova, N., J. Casciari, et al. (2012). "Effect of high-dose intravenous vitamin C on inflammation in cancer patients." J Transl Med 10: 189.

  • Mikirova, Casciari et al. 2012)

  • ​

  •          Ichim, T. E., B. Minev, et al. (2011). "Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?" J Transl Med 9: 25. (Ichim, Minev et al. 2011)

  • ​

 

 

  •          Yeom, C. H., G. C. Jung, et al. (2007). "Changes of Terminal Cancer Patients' Health-related Quality of Life after High Dose Vitamin C Administration." J Korean Med Sci 22(1): 7-11.

  • Yeom, Jung et al. 2007)

  • ​

Schwerpunkt auf Pharmakokinetik und chemotherapeutisches Potential 

 

·         Min- Seok, S., K. Ja-Kyung and S. Jae-Yong (2015). "High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma." Yonsei Med J 2015 56: 1449-1452. High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma

·        

  •          Hoffer, L. J., L. Robitaille, et al. (2015). "High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial." PLoS One 10(4): e0120228.

High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial

 

  •          Fritz, H., G. Flower, et al. (2014). "Intravenous Vitamin C and Cancer: A Systematic Review." Integr Cancer Ther 13(4): 280-300.

Intravenous Vitamin C and Cancer: A Systematic Review. - PubMed - NCBI

 

  •          Gonzalez, M. J. and J. R. Miranda-Massari (2014). "New Insights on Vitamin C and Cancer." Springer Briefs in Cancer Research.

 

  •          Stephenson, C. M., R. D. Levin, et al. (2013). "Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer." Cancer Chemother Pharmacol 72(1): 139-146.

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer

 

 

  •          Hoffer, L. J., M. Levine, et al. (2008). "Phase I clinical trial of i.v. ascorbic acid in advanced malignancy." Ann Oncol.

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

 

  •          Drisko, J. A., J. Chapman, et al. (2003). "The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer." J Am Coll Nutr 22(2): 118-123.

The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. - PubMed - NCBI

 

Experimentelle Studien

 

 

 

 

  •          Venturelli, S., T. W. Sinnberg, et al. (2014). "Epigenetic impacts of ascorbate on human metastatic melanoma cells." Front Oncol 4: 227.

Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells

 

 

  •          Yeom, C. H., G. Lee, et al. (2009). "High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis." J Transl Med 7: 70.

  • Yeom, Lee et al. 2009)

  • ​

 

  •          Chen, Q., M. G. Espey, et al. (2008). "Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice." Proc Natl Acad Sci U S A.

  • Chen, Espey et al. 2008)

  • ​

 

  •          Chen, Q., M. G. Espey, et al. (2005). "Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues." Proc Natl Acad Sci U S A.

(Chen, Espey et al. 2005)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1224653/pdf/pnas-0506390102.pdf

​

​

​

​

​

​

​

​

​

​

bottom of page